*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.*
*Information and documents given to ASX become ASX's property and may be made public.*

**Introduced 30/9/2001. Amended 01/01/11**

| | |
|---|---|
| **Name of Entity:** | **Antisense Therapeutics Limited** (ASX:ANP) |
| **ABN:** | 41 095 060 745 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director:** | Dr Chris Belyea |
| **Date of Last Notice:** | 23 December 2013 |

**Part 1 – Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or Indirect Interest** | Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | Director Related Entity |
| **Date of change** | 12 November 2014 |
| **No. of securities held prior to change** | |
| **Class** | Ordinary Shares |
| **Number acquired** | |

| | Shares | Options |
|---|---|---|
| **Direct** | - | 24,000 |
| **Indirect** | 111,666 | 37,222 |
| **Total** | **111,666** | **61,222** |

| | Shares | Options |
|---|---|---|
| **Direct** | - | - |
| **Indirect** | 173,913 | - |
| **Total** | **173,913** | - |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Number disposed** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>-</td></tr></table> |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | $0.115 per share |
| **No. of securities held after change** | <table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td></td><td>24,000</td></tr><tr><td>**Indirect**</td><td>285,579</td><td>37,222</td></tr><tr><td>**Total**</td><td>**285,579**</td><td>**61,222**</td></tr></table> |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Director participation in capital raising as approved by shareholders at 2014 AGM |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |